drugset / Trial / NCT00382148
A Study of Xolair in Peanut-Allergic Subjects Previously Enrolled in Study Q2788g
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase IIb, multicenter, open-label study available to active (Xolair) and control (placebo) subjects who have completed their final visit (or early termination visit, if applicable) for Study Q2788g, who meet the eligibility criteria of this study, and who provide consent to participate in this study.
Timeline
- Start
- 2006-11
- Primary completion
- 2008-06-28
- Completion
- 2008-06-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Omalizumab | Monoclonal antibody | — | Subcutaneous |
Indications
No indication recorded.